SCN8A Epilepsy clinical trials at UCSF
2 in progress, 1 open to eligible people
SCN8A Epilepsy is a type of epilepsy caused by a gene mutation. There is a clinical trial at UCSF testing a new treatment called NBI-921352 for people with SCN8A-DEE. The trial will look at how well it works, how safe it is, and how the body processes it. Another trial is happening, but it's not accepting new participants.
NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
open to eligible people ages 2-21
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
San Francisco, California and other locations
Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Subjects With SCN8A-DEE
Sorry, accepting new patients by invitation only
Extension Study to Evaluate how safe and tolerable the drug NBI-921352 is when used as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
San Francisco, California and other locations
Last updated: